Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Evaluate Launches Enhanced Orphan Drug Intelligence

Published: Monday, July 15, 2013
Last Updated: Monday, July 15, 2013
Bookmark and Share
Available to EvaluatePharma® service clients beginning June 20, 2013.

The worldwide orphan drug market is set to reach $127 billion by 2018, accounting for nearly 16 percent of total prescription drug sales, according to the recently released Orphan Drug Report 2013 from Evaluate.

To better serve its clients’ needs in regard to this growing segment of the pharmaceutical industry, Evaluate has enhanced its EvaluatePharma core product database to include in-depth, fact-based orphan drug analysis with data fields for integrated US, EU and Japan orphan drug designations.

The enhanced orphan drug content will be available to all EvaluatePharma service clients on June 20, 2013.

“As a company, we are focused on our clients’ success. This enhancement allows our clients to size and track the orphan drug market in order to make more informed, strategic decisions about portfolio strategy, growth opportunities and investments,” said Anthony Raeside, Head of Research at Evaluate.

EvaluatePharma has identified all products that have orphan drug designations filed in the US, EU or Japan, and has defined a clean ‘orphan’ sub-set of products through a fully transparent and documented methodology.

The new enhancement facilitates global analysis of the orphan drug R&D and commercial landscape - including the ability to:
• TRACK the orphan drug market via a transparent methodology
• MAKE orphan drug commercial assessments
• CONDUCT competitive intelligence including patent expiries and exclusivities
• SCREEN for orphan drug licensing opportunities by product, designation, indication
• BENCHMARK current and historical orphan drug deal terms and values
• IDENTIFY the future value of an orphan drug market via consensus sales forecasts
• KNOW the latest news and orphan drug designations and approvals


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Experimental Drug Cancels Effect from Key Intellectual Disability Gene
A University of Wisconsin—Madison researcher who studies the most common genetic intellectual disability has used an experimental drug to reverse — in mice — damage from the mutation that causes the syndrome.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Reprogramming Scorpion Venom
‘Twist of nature’ neutralizes toxin.
Tailoring a Suit for Tumor-Penetrating Cancer Meds
For more than a decade, biomedical researchers have been looking for better ways to deliver cancer-killing medication directly to tumors in the body.
Resurrecting an Abandoned Drug
Previously discarded drug shows promise in helping human cells in a lab dish fight off two different viruses.
Safer, Cheaper, Greener and More Efficient System for Organic Synthesis
The new medium not only supports organic synthesis it also produces considerably higher yields of product than pure organic solvents.
Fighting Prostate Cancer
Identifying the most promising compounds which can be used as medications for prostate cancer.
Collaboration to Develop Cancer Therapeutics
Major license agreement with Merck, enabled by Blavatnik Biomedical Accelerator, aims to develop therapy for most common form of acute leukemia.
Faster UVA Molecular Analysis Technology
There are people in the world – chemical engineers, astronomers, national defense scientists investigating an explosion – who need to know just what something is made of, down to the molecular level.
Scientists Synthesize Anti-Cancer Agent
A team led by Rice University synthetic organic chemist K.C. Nicolaou has developed a new process for the synthesis of a series of potent anti-cancer agents originally found in bacteria.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!